Katori M, Majima M, Mohsin S S, Hanazuka M, Mizogami S, Oh-ishi S
Department of Pharmacology, Kitasato University School of Medicine, Kanagawa, Japan.
Agents Actions Suppl. 1992;38 ( Pt 3):235-42.
Deoxycorticosterone acetate (DOCA)-salt hypertension was induced in Brown Norway (BN) kininogen-deficient rats (BN-Ka) and normal rats from the same strain (BN-Ki) after nephrectomy. Systolic blood pressure, which was determined by the tail-cuff method, of BN-Ki increased gradually during this treatment. In contrast, the blood pressure of mutant BN-Ka increased rapidly 2 weeks after the onset of the treatment. Urinary excretion of active kallikrein and prokallikrein increased at the same degree in rats of both strains during this treatment. Significant increase in urinary sodium excretion was observed with a tendency to increase in urine volume during the treatment in normal BN-Ki rats, whereas both parameters were essentially not increased in mutant BN-Ka rats, which could not generate urinary kinin. Aprotinin infusion by osmotic minipump to normal BN-Ki rats during the DOCA-salt treatment resulted in significant further increase in the systolic blood pressure.
在肾切除术后,对棕色挪威(BN)激肽原缺乏大鼠(BN-Ka)和同一品系的正常大鼠(BN-Ki)诱导产生醋酸脱氧皮质酮(DOCA)-盐高血压。通过尾套法测定的BN-Ki大鼠收缩压在该治疗过程中逐渐升高。相比之下,突变型BN-Ka大鼠的血压在治疗开始2周后迅速升高。在此治疗期间,两种品系大鼠的活性激肽释放酶和激肽原的尿排泄量以相同程度增加。在正常BN-Ki大鼠治疗期间,观察到尿钠排泄显著增加,尿量有增加趋势,而突变型BN-Ka大鼠这两个参数基本未增加,因为它们无法产生尿激肽。在DOCA-盐治疗期间,通过渗透微型泵向正常BN-Ki大鼠输注抑肽酶导致收缩压进一步显著升高。